Pear Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0046
- Today's High:
- $0.0061
- Open Price:
- $0.005
- 52W Low:
- $0.004
- 52W High:
- $0.2162
- Prev. Close:
- $0.0045
- Volume:
- 471836
Company Statistics
- Market Cap.:
- $0
- Book Value:
- -19.936
- Revenue TTM:
- $1.69 million
- Operating Margin TTM:
- -5697.33%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Pear Therapeutics Inc had its IPO on 2021-03-26 under the ticker symbol PEARW.
The company operates in the sector and industry. Pear Therapeutics Inc has a staff strength of 200 employees.
Stock update
Shares of Pear Therapeutics Inc opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0.01, and closed at $0.01.
This is a +31.11% increase from the previous day's closing price.
A total volume of 471,836 shares were traded at the close of the day’s session.
In the last one week, shares of Pear Therapeutics Inc have slipped by -62.66%.
Pear Therapeutics Inc's Key Ratios
Pear Therapeutics Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Pear Therapeutics Inc’s revenue was $1.69 million with a gross profit of $0 and an EBITDA of $-95100000. The EBITDA ratio measures Pear Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pear Therapeutics Inc’s operating margin was -5697.33% while its return on assets stood at 0% with a return of equity of 0%.
In Q4, Pear Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 85.5%.
Pear Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-10.101 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pear Therapeutics Inc’s profitability.
Pear Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Pear Therapeutics Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $95.13 million
- Total Liabilities
- $49.44 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.39 million
- Dividend Payout Ratio
- 0%
Pear Therapeutics Inc ended 2024 with $95.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.13 million while shareholder equity stood at $30.59 million.
Pear Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $49.44 million in other current liabilities, 14000.00 in common stock, $-323474000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.30 million and cash and short-term investments were $59.27 million. The company’s total short-term debt was $1,984,000 while long-term debt stood at $0.
Pear Therapeutics Inc’s total current assets stands at $72.96 million while long-term investments were $0 and short-term investments were $10.97 million. Its net receivables were $6.94 million compared to accounts payable of $3.26 million and inventory worth $0.
In 2024, Pear Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $2.39 million.
Comparatively, Pear Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $0.2162
- 52-Week Low
- $0.004
- Analyst Target Price
- $
Pear Therapeutics Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $0.2162 and a 52-week low of $0.2162. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.09 and 200-day moving average was $0.24 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Pear Therapeutics Inc
Most Active
Top Gainers
Top Losers
About
Pear Therapeutics, Inc. engages in developing and commercializing software-based medicines. The company has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurologic conditions. Its products include PearConnect, a patient service center for prescription digital therapeutics; reSET for the treatment of substance use disorder; reSET-O for the treatment of opioid use disorder; and Somryst for the treatment of chronic insomnia. The company was founded in 2013 and is based in Boston, Massachusetts.